Temporal Concept
FDA Approves Ono Pharmaceutical’s Romvimza for Rare Joint Tumor
Romvimza, tenosynovial giant cell tumor (TGCT), FDA approval, Ono Pharmaceutical, Deciphera acquisition, kinase inhibitor, rare cancer treatment
Biogen and Stoke Therapeutics Partner on Promising Dravet Syndrome Treatment
Biogen, Stoke Therapeutics, zorevunersen, Dravet syndrome, antisense oligonucleotide, rare epilepsy, drug development, pharmaceutical partnership
Federal Judge Issues Nationwide Injunction on NIH Funding Cuts After Multi-State Lawsuit
NIH funding, research grants, federal judge, temporary restraining order, lawsuit, indirect costs, Trump administration
Sanofi’s E. coli Vaccine Fails Phase 3 Trial, Resulting in $250M Impairment Charge
Sanofi, Johnson & Johnson, E. coli vaccine, Phase 3 failure, impairment charge, clinical trial discontinuation
Federal Judge Temporarily Blocks NIH’s Drastic Cut to Research Funding After Universities and States Sue
NIH funding cuts, indirect costs, research grants, university lawsuit, temporary restraining order, biomedical research
SpringWorks Therapeutics Secures FDA Approval for Gomekli to Treat NF1-Related Tumors
SpringWorks Therapeutics, Gomekli, mirdametinib, FDA approval, neurofibromatosis type 1 (NF1), plexiform neurofibromas (PN), rare disease treatment, MEK inhibitor
Eisai Anticipates Growth Acceleration for Alzheimer’s Drug Leqembi Despite Slow Initial Uptake
Leqembi, Alzheimer’s disease, Eisai, expansion phase, sales growth, diagnostics, maintenance dosing, patient adoption
LinusBio Introduces ClearStrand-ASD: Revolutionary Autism Diagnostic Aid Using Hair Analysis
LinusBio, ClearStrand-ASD, autism diagnostic, hair analysis, biomarker test, early detection, negative predictive value, exposome medicine
World Cancer Day 2025: Innovations in Prevention, Detection, and Treatment
cancer research, immunotherapy, early detection, AI in oncology, novel therapies, clinical trials, personalized medicine
FDA Approves Axsome’s Symbravo for Rapid Migraine Relief
Symbravo, meloxicam, rizatriptan, FDA approval, acute migraine treatment, rapid-acting, Axsome Therapeutics